Physician profile
Carlos E Lara
NPI 1265475511
$2,924.80
in general payments reported to CMS, 2019-2025
31 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $786 · 2021: $151 · 2022: $98.11 · 2023: $381 · 2024: $299 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.00 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $424.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $296.74 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $270.88 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.83 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $189.78 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Watermark Medical, INC. | $187.21 | 2020 | |
| Amgen INC. | $183.40 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $174.37 | 2021-2024 | |
| Pfizer INC. | $166.94 | 2019-2024 | |
| Allergan, INC. | $123.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $118.50 | 2019-2024 | |
| Amarin Pharma, INC. | $67.04 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.23 | 2022-2025 | |
| Grifols USA, LLC | $49.28 | 2024 | Prolastin-C Liquid |
| Dexcom, INC. | $43.81 | 2022-2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.44 | 2020-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $34.90 | 2022-2023 | Proclaim |
| Otsuka America Pharmaceutical, INC. | $27.43 | 2023 | Jynarque |
| Teva Pharmaceuticals USA, INC. | $25.44 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $23.70 | 2025 | Opsynvi, Uptravi |
| Boston Scientific Corporation | $23.54 | 2025 | General - Pain Management |
| Vifor Pharma, INC. | $23.46 | 2023 | Veltassa |
| Corcept Therapeutics | $18.21 | 2025 | Korlym |
| Astellas Pharma US INC | $17.96 | 2020 | |
| Axsome Therapeutics, INC. | $16.59 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $16.43 | 2020 | |
| Horizon Therapeutics Plc | $16.16 | 2021 | |
| Averitas Pharma INC. | $13.89 | 2023 | Qutenza |
| Viatris Specialty LLC | $13.74 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $13.53 | 2024 | Voquezna |
| Mylan Specialty L.P. | $13.32 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.